Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy

This study is currently recruiting participants.
Verified February 2013 by Columbia University
Sponsor:
Collaborator:
Breast Cancer Research Foundation
Information provided by (Responsible Party):
Dawn L. Hershman, Columbia University
ClinicalTrials.gov Identifier:
NCT01163682
First received: July 14, 2010
Last updated: February 19, 2013
Last verified: February 2013

July 14, 2010
February 19, 2013
May 2010
December 2013   (final data collection date for primary outcome measure)
Compare the difference in neuropathic pain between the two arms [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Neuropathic pain as measured by the mean Brief Pain Inventory-Short Form (BPI-SF) worst pain score, which will be administered at study entry, 6 weeks, 12 weeks, and 16 weeks
Same as current
Complete list of historical versions of study NCT01163682 on ClinicalTrials.gov Archive Site
  • Compare the difference of fact-taxane scores and quality of life measures between the groups [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    FACT-Tax quality of life assessment will be administered at study entry, 6 weeks, 12 weeks, and 16 weeks.
  • Compare the extent of neurologic dysfunction between the two arms [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Neurologic dysfunction will be assessed via the Grooved Pegboard test, which will be administered at study entry, 6 weeks, 12 weeks and 16 weeks.
  • Compare differences in change in pro-inflammatory cytokines [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Blood draw for assays of interleukin 1 beta (IL-1 beta), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) taken at study entry, 6 weeks, 12 weeks, and 16 weeks
  • Compare the difference of fact-taxane scores and quality of life measures between the groups [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    FACT-Tax quality of life assessment will be administered at study entry, 6 weeks, 12 weeks, and 16 weeks.
  • Compare the extent of neurologic dysfunction between the two arms [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Neurologic dysfunction will be assessed via the Grooved Pegboard test, which will be administered at study entry, 6 weeks, 12 weeks and 16 weeks.
  • Compare differences in change in pro-inflammatory cytokines [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Blood draw for assays of IL-1 beta, IL-6, and TNF-alpha taken at study entry, 6 weeks, 12 weeks, and 16 weeks
Not Provided
Not Provided
 
Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy
Randomized Sham Controlled Trial of Weekly Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy

This is a two arm randomized pilot study. This study seeks to determine if 12 weeks of weekly electroacupuncture will prevent or decrease neuropathic pain in breast cancer patients receiving 12 weekly treatments of taxane treatment.

The primary endpoint of this study is to compare the difference in neuropathic pain as measured by the mean Brief Pain Inventory-Short Form (BPI-SF) worse pain score at 12 weeks between the two arms. The Brief Pain Inventory-Short Form is a well validated clinical tool used frequently to assess severity of pain and its effect on daily functions. BPI-SF also monitors the effects of treatment on pain in patients with cancer and other chronic illnesses. The instrument gives several ratings of the intensity and severity of pain and the degree of pain interference on activity, mood, sleep, relations with others and work. The questionnaire uses a 0-10 scale for subject ratings and takes five minutes to complete. We consider a reduction of 2 or more points on the BPI-SF worst pain item to correspond with a clinically meaningful decrease in pain.

The secondary endpoints include other efficacy outcomes such as quality of life measures, extent of neurological dysfunction, blood levels of pro-inflammatory cytokines, and adverse events.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
  • Taxane Induced Neuropathy
  • Breast Cancer
  • Other: Electro-acupuncture
    Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
  • Other: Sham acupuncture
    Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The elecrto-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
  • Active Comparator: Electro-acupuncture
    45 minute sessions scheduled once a week for 12 weeks.
    Intervention: Other: Electro-acupuncture
  • Sham Comparator: Sham acupuncture
    45 minute sessions scheduled once a week for 12 weeks
    Intervention: Other: Sham acupuncture
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age>21 years
  • History of stage I-III breast cancer
  • Patient scheduled to be receiving weekly adjuvant paclitaxel for 12 weeks
  • Signed informed consent

Exclusion Criteria:

  • Previous treatment with acupuncture
  • Diabetic Neuropathy or other neurological conditions
  • Inflammatory, metabolic or neuropathic arthropathies
  • Current narcotic use
  • Severe concomitant illnesses
  • Severe coagulopathy or bleeding disorder
  • Dermatological disease within the acupuncture area
Female
21 Years and older
No
Contact: Herbert Irving Comprehensive Cancer Center Clinical Research Management Office 212-305-8615
United States
 
NCT01163682
AAAE7054
No
Dawn L. Hershman, Columbia University
Columbia University
Breast Cancer Research Foundation
Principal Investigator: Dawn L Hershman, MD, MS Columbia University
Columbia University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP